Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model

[1]  R. Langer,et al.  Poly(Ethylene Oxide)-Modified Poly(β-Amino Ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs: Part 2. In Vivo Distribution and Tumor Localization Studies , 2005, Pharmaceutical Research.

[2]  R. Kerbel,et al.  Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. , 2005, Cancer research.

[3]  Mansoor Amiji,et al.  Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. , 2005, Molecular pharmaceutics.

[4]  Paul Kinahan,et al.  Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  R. Kaushik,et al.  Poly-ϵ-caprolactone microspheres and nanospheres: an overview , 2004 .

[6]  J. Minna,et al.  Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[7]  Robert Langer,et al.  Small-scale systems for in vivo drug delivery , 2003, Nature Biotechnology.

[8]  I. Fichtner,et al.  A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. , 2003, Cancer research.

[9]  Robert Langer,et al.  Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Mansoor M. Amiji,et al.  BIODEGRADABLE POLY (E-CAPROLACTONE) NANOPARTICLES FOR TUMOR-TARGETED DELIVERY OF TAMOXIFEN , 2002 .

[11]  Chong-K. Kim,et al.  Recent progress in drug delivery systems for anticancer agents , 2002, Archives of pharmacal research.

[12]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[13]  Robert Langer,et al.  pH-Responsive Polymer Microspheres: Rapid Release of Encapsulated Material within the Range of Intracellular pH** , 2001 .

[14]  K. Kataoka,et al.  Block copolymer micelles for drug delivery: design, characterization and biological significance. , 2001, Advanced drug delivery reviews.

[15]  Robert Langer,et al.  Degradable Poly(β-amino esters): Synthesis, Characterization, and Self-Assembly with Plasmid DNA , 2000 .

[16]  R K Jain,et al.  Vascular permeability in a human tumour xenograft: molecular charge dependence , 2000, British Journal of Cancer.

[17]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[18]  J. Kopeček,et al.  Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. , 1999, Journal of Controlled Release.

[19]  R K Jain,et al.  Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.

[20]  V. Sinha,et al.  Bioabsorbable polymers for implantable therapeutic systems. , 1998, Drug development and industrial pharmacy.

[21]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[22]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[23]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[24]  Kinam Park,et al.  Surface Modification of Polymeric Biomaterials with Poly(ethylene oxide): A Steric Repulsion Approach , 1993 .

[25]  Robert Langer,et al.  Polymers of biological and biomedical significance , 1993 .

[26]  V. Kolb-Bachofen,et al.  Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. , 1993, Biochimica et biophysica acta.

[27]  K. Caldwell,et al.  Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. , 1993, Biomaterials.

[28]  P. Houghton,et al.  O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Moatamed,et al.  The intracellular degradation of poly(ε-caprolactone) , 1985 .

[30]  J. Haveman,et al.  The relevance of tumour pH to the treatment of malignant disease. , 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  G L Kimmel,et al.  Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (epsilon-caprolactone), and their copolymers in vivo. , 1981, Biomaterials.

[32]  M. Hashida,et al.  Effect of Particle Size and Charge on the Disposition of Lipid Carriers After Intratumoral Injection into Tissue-isolated Tumors , 2004, Pharmaceutical Research.

[33]  R. Kaushik,et al.  Poly-epsilon-caprolactone microspheres and nanospheres: an overview. , 2004, International journal of pharmaceutics.

[34]  G. Barratt,et al.  Colloidal drug carriers: achievements and perspectives , 2003, Cellular and Molecular Life Sciences CMLS.

[35]  M. Amiji,et al.  Biodegradable poly(epsilon -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. , 2002, International journal of pharmaceutics.

[36]  R. Jain,et al.  Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. , 2001, Cancer research.

[37]  F. Kratz,et al.  Drug-polymer conjugates containing acid-cleavable bonds. , 1999, Critical reviews in therapeutic drug carrier systems.

[38]  V. Diehl,et al.  Lymphocyte predominant Hodgkin's disease: pathology and clinical implication. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Kinam Park,et al.  Prevention of protein adsorption and platelet adhesion on surfaces by PEO/PPO/PEO triblock copolymers. , 1992, Biomaterials.

[40]  S C Woodward,et al.  The intracellular degradation of poly(epsilon-caprolactone). , 1985, Journal of biomedical materials research.

[41]  A. Schindler,et al.  Biodegradable drug delivery systems based on aliphatic polyesters: application to contraceptives and narcotic antagonists. , 1981, NIDA research monograph.